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Abstract.  F9 teratocarcinoma stem cells treated with 
retinoic acid (RA) and dibutyryl cAMP (but2 cAMP) 
differentiate into embryonic parietal endoderm.  Using 
heparin-attinity chromatography, endothelial cell 
proliferation assays, immunoprecipitation, and Western 
analysis with antibodies specific for acidic and basic 
fibroblast growth factors (FGFs), we detected biologi- 
cally active FGF in F9 cells only after differentiation. 
A  bovine basic FGF cDNA probe hybridized to 2.2-kb 
mRNAs in both F9 stem and parietal endoderm cells 
and to a  3.8-kb mRNA in F9 stem cells. A  genomic 
DNA probe for acidic FGF hybridized to a  5.8-6.0-kb 
mRNA in both F9 stem and parietal endoderm 
cells, and to a 6.0-6.3-kb  mRNA only in parietal 
endoderm cells. Although these FGF mRNAs were 
present in the stem cells, we could find no evidence 
that F9 stem cells synthesize FGFs, whereas differen- 
tiated F9 cells synthesized both acidic and basic FGF- 
like proteins. We conclude that biologically active fac- 
tors with properties characteristic of acidic and basic 
FGF are expressed by F9 parietal endoderm cells after 
differentiation. Differentiating embryonic parietal endo- 
derm thus may serve as a  source of FGF molecules in 
the developing blastocyst, where these factors appear 
to play a  central role in subsequent embryogenesis. 
F 
9 murine teratocarcinoma stem cells are analogous in 
many respects to the cells of the inner cell mass of the 
mouse blastocyst (Martin, 1980).  Within 3-4 d after 
treatment of monolayer cultures with retinoic acid (RA)' and 
dibutyryl cAMP  (but2 cAMP),  F9  stem cells irreversibly 
differentiate into a homogeneous population of ceils indistin- 
guishable from extraembryonic parietal endoderm (Strick- 
land et al., 1980). These parietal endoderm cells synthesize 
plasminogen activator, laminin, type IV collagen, and mem- 
brane-bound heparan sulfate (Strickland et al., 1980; Wang 
et al., 1985; Kapoor and Prehm, 1983),  keratins (Vasseur et 
al.,  1985;  Singer et al.,  1986),  and H-2 antigen (Croce et 
al., 1981). This system has been used by a number of workers 
as a model for the study of the differentiation of embryonic 
inner cell mass cells and has provided a means for identify- 
ing the biochemical and molecular events involved in this 
process. 
Another application for this system has been the study of 
tumorigenesis. Teratocarcinoma stem cell lines character- 
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istically undergo continuous proliferation in vitro and are 
tumorigenic in vivo, whereas the differentiated cells are not 
tumorigenic (Martin, 1980). These observations led investi- 
gators  to  compare  the  growth  requirements  of stem and 
differentiated cells in a number of teratocarcinoma cell lines 
(Heath et al.,  1981; Gudas et al.,  1983;  Heath and Isacke, 
1984).  Several lines acquire specific growth factor receptors 
as a function of differentiation. For example, differentiated 
PC-13 and OC-15S1 cells bind increased amounts of epider- 
mal growth factor (EGF)  (Rees et al.,  1979)  and insulin 
(Heath et al., 1981) after differentiation. These studies sug- 
gest that the inability of these differentiated cells to form 
tumors correlates with an increased responsiveness to exter- 
nal signals of growth control. 
In contrast,  undifferentiated teratocarcinoma stem cells 
were reported to secrete growth factors. For example, PSA-1- 
G and F9 stem cells secrete a platelet-derived growth factor 
(PDGF)-Iike molecule (Gudas et al.,  1983;  Rizzino and 
Bowen-Pope,  1985).  Another undifferentiated teratocarci- 
noma cell line,  PC13,  secretes an uncharacterized growth 
factor, embryonal carcinoma-derived growth factor, which 
has been shown to stimulate the proliferation of fibroblasts 
and the PC13 differentiated cells (Heath and Isacke, 1984). 
Both of these growth factors are secreted by stem cells and 
are either absent or present at lower levels in the media of 
the  corresponding differentiated cells.  Although it is  not 
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bryo, evidence is rapidly emerging that dramatic changes oc- 
cur in the profiles of growth factor production as a function 
of  differentiation.  We  have  examined  the  F9  stem  and 
differentiated teratocarcinoma cells for the presence of an- 
other  well-characterized  class  of  cellular  mitogens,  the 
fibroblast growth factors (FGFs). 
In recent years, FGFs have been identified in numerous 
normal tissues, and in association with a  number of solid 
tumors  (for  reviews  see  Folkman and  Klagsbrun,  1987; 
DAmore  and  Braunhut,  1988).  These  factors have  been 
purified to homogeneity using their unusual affinity for the 
glycosaminoglycan heparin  (Shing  et  al.,  1984).  It  has 
emerged that there are two classes of heparin-binding growth 
factors, class  1 and class 2,  which are  synonymous with 
acidic (a) and basic (b) FGF, respectively. 
FGF has been identified in many tissues, including pitu- 
itary (Bohlen et al., 1984),  placenta (Gospodarowicz et al., 
1985a),  corpus luteum (Gospodarowicz et al., 1985b), adre- 
nal gland (Gospodarowicz et al.,  1986),  and kidney (Baird 
et al.,  1985).  Furthermore,  endothelial cell mitogens as- 
sociated with a  number of tumors,  including a  rat chon- 
drosarcoma, a human melanoma, and a hepatoma, are struc- 
turally related if not identical to bFGF (Klagsbrun et al., 
1986). aFGF appears to have a more limited distribution and 
has  been  found  in  hypothalamus  (Klagsbrun  and  Shing, 
1985),  retina (DAmore and Klagsbrun,  1984),  testis (Feig 
et al., 1983),  and bone (Hauschka et al.,  1986),  and in as- 
sociation with some human tumor cell lines (Lobb et al., 
1986). 
The amino acid sequence for bovine bFGF is known (Esch 
et al., 1985) and 7.0- and 3.7-kb mRNA transcripts have been 
identified  in  bovine  adrenal  cortex-derived  and  bovine 
brain-derived capillary endothelial cells (Schweigerer et al., 
1987a).  Rodent tissues screened with a eDNA encoding rat 
bFGF revealed a single 6.0-kb mRNA in rat hypothalamus 
and brain cortex tissue (Shimasaki et al., 1988), and human 
fibroblasts express mRNA transcripts encoding bFGF of 7, 
3.7, 2.2, and 1.5 kb in size (Steinfeld et al.,  1988). 
The amino acid sequence of aFGF has been determined 
(Gimenez-Gallego et al., 1985) and a single, 4.8-kb mRNA 
transcript encoding aFGF has been reported in human brain 
stem using Northern analysis (Jaye et al.,  1986).  There are 
few reports in the literature on the sizes of the transcripts en- 
coding aFGF in other species. 
Factors with properties  similar but not identical to the 
FGFs have been detected in F9 cells (van Veggel et al., 1987; 
Rizzino et al.,  1988) and may relate to the presence in F9 
ceils of mRNA transcripts encoding two oncogenes in the 
FGF family, hst I and int-2 (Yoshida et al., 1988).  The bio- 
logic properties of the protein products of these genes are 
now known, but the message sizes are distinctly different 
from mRNA encoding the FGFs (Yoshida et al.,  1988).  F9 
stem cells express high amounts of a 3.0-kb transcript for hst 
1, which decreases after differentiation. Conversely, mRNAs 
encoding int-2 of 2.9,  2.7, 1.8, and  1.6 kb are detected in 
greater abundance in F9 parietal endoderm cells (Yoshida et 
al., 1988).  The significance of the differential expression of 
mRNAs encoding these two oncogenes in F9 cells and their 
presence during early embryogenesis is not known. In this 
report, we examine the expression of FGF in F9 cells as a 
function of differentiation. 
Materials and Methods 
Materials 
RA (all-trans) and most other chemicals were purchased from Sigma Chem- 
ical Co. (St.  Louis, MO).  [35S]Methionine  (1,131 Ci/mmol) was obtained 
from New England Nuclear (Boston, MA). The eDNA clones for basic and 
acidic FGF were generously provided by Dr. John Fiddes (California Bio- 
technology, Inc., Mountain View, CA). Heparin-Sepharose was purchased 
from Pharmacia Fine Chemicals (Uppsala,  Sweden). Reagents used for 
Na2DodSO4 PAGE were from Bio-Rad Laboratories (Richmond, CA). Tis- 
sue culture reagents were from Gibco Laboratories (Grand Island, NY). 
Cell Culture 
The F9 teratocarcinoma stem cells were grown on gelatinized tissue culture 
(Falcon  Labware,  Oxnard,  CA)  dishes  in  DME  containing  10%  heat- 
inactivated calf serum. For differentiation studies, cells were treated with 
RA (1  x  10  -6 M), but2 cAMP (2.5  ×  10  -4 M), and theophylline (400 #M) 
for at least 72 h. Details of this differentiation protocol have been described 
previously (Wang et al.,  1985). 
Bovine capillary endothelial cells from adrenal cortex were provided by 
Dr. J.  Folkman (The Children's Hospital, Boston, MA). The endothelial 
cells were grown in DME containing 10% calf serum and cells were main- 
rained on gelatinized tissue culture dishes from Nunc (Vanguard  Interna- 
tional, NJ). Endothelial cell proliferation studies were conducted by plating 
the cells at 1 x  l& per well in 24 multiwell gelatinized dishes. The cells 
were allowed to attach overnight and washed, and 0.5 ml of fresh media was 
added with aliquots of fractions to be tested. 72 h later cells were washed 
and trypsinized and cell numbers were determined electronically with a 
counter (Coulter Electronics, Inc., Hialeah, FL). The SK hepatoma cells, 
provided by  Dr.  Michael  Klaggbrun  (The  Children's Hospital,  Boston, 
MA), were cultured in DME plus 10%  calf serum. 
Preparation of Cell Extracts 
F9 stem and parietal endoderm cells were harvested from monolayer cul- 
tures by rinsing in cold PBS three times, followed by trypsinization, or in 
some experiments removal by scraping with a rubber policeman. Approxi- 
mately 1 x  108-1 x  109 stem or RA-treated cells were harves~l, depend- 
ing on the experiment. Cells were washed again in PBS, centrifuged at 2,000 
rpm for 10 rain at 4°C, resuspended rapidly in a small volume (0.6-1.2  ml) 
of 1 M  NaC1 and 0.01 M  Tris-HCI buffer,  pH 7.6, and sonicated on ice 
(model W370;  Heat Systems-Ultrasonics Inc.,  Farmingdale, NY;  micro- 
probe setting 2, twice for 10 s each). Cell extracts were then incubated for 
1 h on ice in the presence or absence of protease inhibitors: 1 t~g/ml ieupep- 
tin, 2.75 #g/ml pepstatin, and 175/xg/ml PMSF as indicated. After centrifu- 
gation at 10,000 rpm for 5 min at 4°C in a microfuge, the supernatant, in 
a volume of '~0.4-1.0 ml, was stored at  -20°C before being assayed for 
mitogenic activity.  In some experiments, affinity-purified antiserum to por- 
cine transforming growth factor (TGF-B)  (1:1,000) (R&D Systems, Inc., 
Minneapolis, MN) was added directly to the extract or pooled fractions for 
1 h at 4°C. Staphylococcal protein A-Sepharose was then added to the sus- 
pension and the mixture incubated overnight at 4°C with mixing, the beads 
were pelleted at 1,000 g, and the supernatants were assayed in parallel with 
an untreated extract for their effect on capillary endothelial cell growth. 
Preparation of Conditioned Media 
Conditioned media were prepared from F9 stem and parietal endoderm cell 
cultures that had been treated with RA plus but2 cAMP for 4 d by washing 
,x,5 x  10  s P9 cells three times with sterile PBS. The cells were then placed 
in DME plus 10% calf serum with RA and but2 cAMP for 48 h. Approxi- 
mately  14  ml of DME  was used for each flask of 5  x  107 cells. The 
medium was then centrifuged at 5,000  rpm for 12 min at 4°C and frozen 
at  -20°C. 
Column Chromatography 
Cell extracts, prepared as described above, were diluted to 0.1 M NaCI, in 
PBS buffer, pH 7.6, and applied to a column of beparin-Sepharose (1  x  20 
cm,  10 ml) that had been previously washed with 3.0 M  NaCI and PBS 
buffer, pH 7.6, and reequilibrated with PBS buffer, pH 7.6. After loading the 
sample, the column was clamped overnight at 4°C to allow for maximal 
binding. The column was then washed with 3 column vol of PBS buffer, pH 
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tioned media, the conditioned media or an equivalent volume of uncondi- 
tioned media were subjected to heparin-Sepharose chromatography by load- 
ing the entire sample at a rate of 10 ml/h onto a heparin-Sepharose column 
(1.5  x  30 cm, 40 ml) prewashed and equilibrated as described above. The 
3T3  cell stimulatory activities were separated on the heparin-Sepharose 
column with a gradient of 0.1-2.0 M NaCI, or in some cases, up to 3.0 M 
NaCI in PBS buffer, pH 7.6, at a flow rate of 10 ml/h. Column fractions were 
screened for their ability to stimulate DNA synthesis in quiescent BALB/c 
31"3 cells by established methods (Klagsbrun et at., 1977).  Briefly, a small 
aliquot (5-50 ~1) of each fraction was added to contact-inhibited and nu- 
trient-starved monolayers of 3T3  cells in the presence of methyl-[3H]thy  - 
midine. 48 h later, the stimulation of DNA synthesis in the 3T3 cultures was 
determined by measuring the amount of [3H]thymidine incorporated into 
TCA-precipitable material by scintillation spectrometry (Klagsbrun et at., 
1977). 
Radiolabeling of  lntraceUular Proteins 
To  determine if FGF  was  being  actively  synthesized by  F9  cells after 
differentiation, 4-h labeling studies were conducted using F9 stem and fully 
differentiated F9 parietal endoderm cells. The parietal endoderm cells were 
obtained by growing F9 teratocarcinoma stem cells in DME containing 10 % 
calf serum with RA (1  x  10  -6 M), but2 cAMP (2.5 x  10  -4 M) and theoph- 
ylline (400 #M) for 5 d, with refeeding on day three. For labeling, the cells 
were rinsed with methionine-free DME and then incubated for 4 h in 16 
ml/dish of medium consisting of methionine-free DME, 5% dialyzed calf 
serum,  and  [35S]methionine  (1,094  Ci/mmol) at 5  /~Ci/ml.  After 4  h  at 
37°C, the radiolabeling medium was removed, the cells were washed three 
times with cold PBS, protease inhibitors were added, and cell extracts were 
harvested and prepared as described above.  Approximately 6  x  l0  s F9 
stem ceils and  1  x  108 RA- and but2 cAMP-treated cells were radiola- 
baled. 
lmmunoprecipitation 
Samples were diluted with distilled water to lower the salt concentration to 
0.1 M NaC1. Gelatin (Difco, Detroit, MI), Triton X-100, and sodium deoxy- 
cholate were then added to yield final concentrations of  2 mg/ml, 0.5 %, and 
0.5 %, respectively. Finally, preimmune antiserum (1:300) or polyclonal an- 
tiserum specific for basic or acidic FGF (1:300) was added and samples were 
incubated for 1 h at 4°C with shaking. The anti-FGF antisera were directed 
against synthetic peptides representing (a) amino acids 1-12 of the amino 
terminus of bFGF; and (b) amino acids 59-90 of the carboxyl terminus of 
aFGE Staphylococcal protein A-Sepharose was then added to the suspen- 
sion and the mixture incubated overnight at 4°C with mixing. The antigen- 
antibody complexes were pelleted by centrifugation and the bead's  were 
washed several times in PBS and finally with deionized distilled H20 before 
elution directly into Na2DodSO4-PAGE  sample buffer and gel electropho- 
resis (Laemmli,  1970). 
Western Blot Analysis 
Cell extracts from 1  ×  10  s F9 stem cells or differentiated parietal endo- 
derrn prepared as described above were diluted with distilled water to lower 
the salt concentration to 0.1 M NaCI. Prewashed heparin-Sepharose beads 
were added to the extracts and incubated overnight at 4°C with mixing. The 
beads were then washed several times with PBS, pH 7.5, and then incubated 
with  1.8 ml of PBS buffer containing 0.8  M  NaCI  for  l  h  at 4°C with 
rotation.  The beads  were washed again  in  PBS,  followed by  two final 
washes with distilled water. Proteins were eluted from the heparin-Sepharose 
beads directly into Na2DOdSO4 PAGE sample buffer, electrophoresed on 
Na2DodSO4-15%  polyacrylamide gels, and transferred electrophoretically 
to BA-83 nitrocellulose paper (Transblot cell; Bio-Rad Laboratories) by de- 
scribed methods (Wadzinski et al., 1987).  After incubation with anti-FGF 
antisera (1:1,000) for 24 h at 4°C, primary antibody binding was visualized 
by serial incubations with biotinylated goat anti-rabbit antibodies, per- 
oxidase-conjugated streptavidin and 4-chloro-l-naphthol (wadzinski et al., 
1987).  Additional antibodies to bFGE raised to a synthetic peptide repre- 
senting an internal portion of the molecule, amino acid residues 33-43 of 
bovine bFGE were used in these studies. 
FGF Sequence-specific  Probes 
The cDNA probe for bovine bFGE given to us by Dr. John Fiddes (Califor- 
nia Biotechnology) was pJJll-1, which contains a  1.4-kb  insert beginning 
,~100  bp upstream of the initial methionine, and extending to •830  bp 
downstream of the translation stop codon (Abraham et al.,  1986). 
The probe for aFGE provided by Dr. John Fiddes, was pCBI-100,  which 
contains a  250-bp AIu fragment of bovine genomic DNA that encodes 
amino acids  1-41 of aFGE plus a portion of an intron (Abraham et al., 
1986).  Before use in Northern analysis, the cDNA and genomic inserts for 
bFGF and aFGF were 32p-labeled  by random hexamer priming. 
Northern Analysis 
F9 stem cells were plated at 1.5  x  106 cells/dish, and after an overnight in- 
cubation at 37°C, RA, but2 cAMP, and theophylline were added to some 
plates as previously described (Wang et at., 1985).  Poly A + RNA was iso- 
lated from F9 stem cells and from P9 cells treated for 4 d with RA and but2 
cAMP to induce differentiation as described (Wang et at.,  1985) and was 
analyzed by Northern blot hybridization as previously described (Wang et 
al.,  1985).  Poly A + RNA was also isolated from SK hepatoma cells. Hy- 
bridization conditions for the cDNA probes were: 6x SSC, 0.05%  sodium 
pyrophosphate, 0.02%  Ficoll, 0.02%  polyvinylpyrrolidone, 0.1% SDS, 100 
/xg/ml denatured sonicated salmon sperm DNA, and 50%  formamide at 
42°C for 24 h. After washing the nitrocellulose blots in 2x  SSC at 42°C 
for the bFGF and aFGF probes, or in lx SSC for the laminin BI, J31, and 
actin probes (Wang et al., 1985),  the blots were exposed to Kodak XAR-5 
film  (Eastman  Kodak,  Rochester,  NY)  at  -70°C  with  an  intensifying 
screen. 
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l~gure 1. Heparin-Sepharose  chro- 
matography of (.4) cell extracts of 
undifferentiated F9  stem cells; 
(B) cell extracts of F9 cells after 
3-d treatment with  RA  and but2 
cAMP; (C) cell extracts; and (D) 
conditioned media from fully dif- 
ferentiated F9 parietal endoderm 
cells, treated for 5 d with RA and 
but2  cAMP.  The bound proteins 
were eluted by applying a  linear 
sodium chloride gradient (- -  -), 
and  growth  factor  activity  was 
monitored by  the  stimulation of 
DNA synthesis in 3T3 cells (-e-). 
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Heparin-binding Mitogenic Activity in F9 Stem Cells 
Over the course of 2-4 d after treatment with RA and but2 
cAME F9 mouse teratocarcinoma stem cells undergo differ- 
entiation to parietal endoderm. We used the affinity of im- 
mobilized heparin for FGF to assay for these proteins in cell 
extracts of F9 stem cells and differentiated F9 parietal endo- 
derm cells. Heparin-Sepharose affinity chromatography of 
the extracts was performed (Shing et al.,  1984),  and frac- 
tions assayed for stimulation of DNA synthesis in BALB/c 
3T3  cells  (Klagsbrun et al.,  1977).  This  assay system is 
widely used for the rapid screening of  a variety of  growth fac- 
tors, including the FGFs. 
The F9 stem cell extract fractionated over heparin-Sepha- 
rose exhibited three peaks of stimulatory activities, which we 
have designated S1, $2, and $3 (Fig. 1 A). The largest peak 
(S1) was present in the void volume and accounted for •80% 
of the stimulatory activity in the starting material. 
Two other peaks of 3T3  cell stimulatory activity, repre- 
senting 10 % of the total activity, eluted from heparin-Sepha- 
rose at 0.25  M and 0.5 M NaCl and are designated $2 and 
$3, respectively. These activities have not been fully charac- 
terized but, because PDGF is known to adhere to heparin and 
elute with 0.5 M NaCl (Shing et al., 1984), it is probable that 
$3 corresponds to the intracellular pool of a PDGF-like fac- 
tor that one of us has reported in the conditioned media of 
F9 stem cells (Gudas et al., 1983).  We recovered '~90% of 
the starting mitogenic activity in the F9 stem cell extract 
from the heparin-Sepharose column.  Approximately  1  x 
105 stem cells yielded one unit of 3T3 cell stimulatory ac- 
tivity. A unit is defined as the amount of mitogen required 
to achieve half-maximal stimulation of DNA synthesis in the 
BALB/c 3T3  cell assay;  maximal stimulation is obtained 
with addition of 20%  calf serum. 
Heparin-binding Mitogenic Activity 
in Differentiated F9 Cells 
3 d after treatment with RA and but2 cAMP,  F9 cells were 
morphologically changed; they were less compact, flatter, 
and more triangular. The extract of RA and but2 cAMP day 
3 F9 cells was subjected to heparin-Sepharose chromatogra- 
phy and was found to contain no 3T3 cell stimulatory activity 
(Fig. 1 B). Thus, the activities represented by peaks S1, $2, 
and $3 in the undifferentiated F9 stem cells are greatly re- 
duced, or absent by 3 d after the induction of differentiation 
of F9 cells into parietal endoderm. 
On day 5 after induction of differentiation, the extracts 
from differentiated F9 parietal endoderm cells contained a 
new 3T3 mitogenic activity (D1), that eluted from heparin- 
Sepharose as a broad peak at 1.5 M NaC1 (Fig.  I  C). That 
1.5 M NaC1 is required to elute the activity from immobi- 
lized heparin strongly suggests that it is a bFGF-like protein. 
Mitogenic Activity Associated with Differentiated F9 
Cells Is Not Secreted 
To determine whether the activity represented by peak D1 
was secreted, media conditioned by a  culture of differen- 
tiated F9 parietal endoderm cells were chromatographed on 
heparin-Sepharose  (Fig.  1  D).  Results  revealed  no  3T3 
stimulatory activity in the conditioned media, even after 10- 
fold concentration by heparin-Sepharose chromatography. 
This is consistent with the recent reports that both basic and 
acidic FGF lack signal peptides (Abraham et al., 1986; Jaye 
et al., 1986) and that they are not secreted by cells that syn- 
thesize these factors in vitro (Vlodavsky et al., 1987b).  Fur- 
ther, this finding distinguishes D1 from factors produced by 
other embryonal carcinoma cell lines, which are reportedly 
secreted (Heath and Isacke,  1984),  and from the potential 
protein product of the int-2 mRNA transcripts expressed by 
these cells (Yoshida et al.,  1988). 
Effects ofF9 Cytosolic Proteins on Endothelial Cells 
TGF-/3 does not adhere to heparin. We, therefore, suspected 
that S1 might be TGF-B. Because TGF-B is known to inhibit 
endothelial cell proliferation (Heimark et al., 1986),  the S1 
fractions were pooled and tested in vitro for their ability to 
modulate the proliferation of bovine capillary endothelial 
cells. S1 inhibited, in a dose-response fashion, the prolifera- 
tion of capillary endothelial cells in response to recombinant 
bFGF (Takeda Chemical Corp, Inc., Osaka, Japan) (Table I). 
The inhibitory activity for bovine capillary endothelial cells 
was reduced by 60% by prior absorption of the cell extract 
with antibodies directed against TGF-/3 (Table I).  Further- 
more, prior acid treatment (Lawrence et al., 1984) of S1 in- 
creases the inhibitory activity, an indication that the latent 
form of TGF-/3 may also be present (data not shown). S1 may 
comprise several factors, but the above findings strongly sug- 
gest that TGF-/3 is at least one of the components in the S1 
peak. 
In contrast, the 3T3 cell mitogenic activity associated with 
the differentiated F9 cells eluted from the heparin-Sepharose 
column at a high molarity of salt, and was found to be mito- 
genic in a  dose-response fashion for bovine capillary en- 
dothelial cells (Fig. 2). Fractions representing the DI peak 
were pooled, dialyzed against PBS, tested in an endothelial 
cell proliferation assay (Fig. 2 A), and the results compared 
directly with the response of the cells to a range of doses of 
brain-derived heparin-purified aFGF (Fig. 2 B) and recom- 
binant bFGF (Fig. 2 C). Each plate contained two internal 
controls: cells receiving PBS (Fig. 2, stippled bars) and cells 
receiving an identical dose,  10 mitogenic units, of recom- 
binant bFGF (Fig.  2, solid bars).  These studies were re- 
peated several times with comparable results and a represen- 
tative experiment is shown in Fig. 2. 
The molarity at which D1 elutes from heparin-Sepharose 
Table L Effect of  Sl on Bovine Capillary Endothelial Cell 
Response to bFGF 
Cell No. 
Addition  ( x 10  -4) 
PBS  1.19 
Basic FGF (3 ng/ml)  13.19 
+  S1  (1 t~l/ml)  13.80 
(5 #l/ml)  12.89 
(20 Id/ml)  8.10 
(50 td/ml)  2.87 
(100 izl/ml)  1.37 
+  S1  (50 td/ml) 
preabsorbed 
with anti-TGF-/3 antibody  8.49 
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Figure 2.  Effect of heparin afffinity-purified  F9 parietal endoderm 
cellular extract on the proliferation of adrenal capillary endothelial 
cells. Capillary endothelial cells were seeded (1  x  104 cells) into 
gelatinized 24-well tissue culture dishes and allowed to attach for 
24 h in DME containing 5% calf serum. Aiiquots from the pooled 
active fractions of the heparin-Sepharose column of F9 parietal en- 
doderm lysates (Fig.  1, D1 ), dialysed against PBS, pH 7.5 (A); (B) 
heparin-purified brain-derived aFGF; and (C) recombinant bFGF 
were added at various doses to triplicate wells. Internal controls of 
PBS  (first stippled bars) and  10-U  doses  of recombinant bFGF 
(solid bars) were included  on each plate.  After 72 h,  cells were 
washed,  trypsinized,  and counted. 
and its ability to stimulate endothelial  cells are characteris- 
tics of the FGFs. The activity in peak D1 was present at "~3 U 
per  1  x  106 cells,  and  50%  of the  starting activity was re- 
covered from the heparin-Sepharose column. A 200-/xl dose 
achieved a level of endothelial  cell proliferation comparable 
to  15  U  of highly  purified  aFGF  or  10  U  of recombinant 
bFGF.  Therefore,  the  total  activity  derived  from  1  ×  108 
differentiated F9 cells is 450 U of aFGF or 300 U  of bFGF. 
Assuming that the biological activity we measure is a 50:50 
mix of acidic and basic FGF and based on published specific 
activities  of acidic  and  basic  FGFs  ("~7  U/ng)  (Klagsbrun 
and  Shing,  1985;  Burgess  et al.,  1985),  the lysates of 1  x 
l0  s differentiated  cells contain  50-75  ng  of FGF  total. 
Analysis of FGF mRNA Levels in Stem and 
Differentiated F9 Teratocarcinoma Cells 
To determine  whether  the genes encoding  basic and  acidic 
FGF were differentially expressed  in F9  stem cells vs.  dif- 
ferentiated  F9 parietal  endoderm  cells,  cDNA probes were 
used to measure the mRNAs encoding FGFs from both cell 
types. 
The bFGF cDNA probe hybridized to two RNAs of 3.8 and 
2.2 kb in F9 stem cells (Fig.  3 A, lane/)  and to the 2.2-kb 
RNA in differentiated  F9  cells  (Fig.  3  A,  lane 2),  whereas 
in the human SK hepatoma line (Fig.  3 A, lane 3), RNAs of 
6.5-7.0,  5.3,  2.2,  and  '~1.0  kb  were  seen  (Fig.  3  A).  No 
change in the steady-state level of the major 2.2-kb RNA was 
observed, but a decrease in the 3.8-kb mRNA transcript was 
detected when F9 stem and F9 parietal endoderm cells were 
compared (Fig.  3 A).  Actin mRNA (Fig.  3 B)  is shown on 
the  same blot  to demonstrate  that equal  amounts  of RNA 
were loaded from F9 stem cells and  F9 parietal  endoderm, 
as the actin mRNA steady-state level does not change during 
differentiation  (Wang  et al.,  1985). 
The F9 parietal endoderm cells expressed other differen- 
tiation-specific markers, such as the mRNAs for laminin B1 
and  J31  (Fig.  3  C,  lane  2),  demonstrating  that  the  treated 
cells had the properties of parietal endoderm cells. The lami- 
nin BI and J31  mRNA expression was extremely low in SK 
hepatoma cells  (Fig.  3  C,  lane 3). 
A  genomic probe specific for bovine aFGF hybridized to 
a 6.0-6.3-kb mRNA only in the differentiated F9 cells (Fig. 
4  A).  In addition,  a  5.8-6.0-kb  mRNA  was observed  in F9 
stem and to a lesser extent in parietal endoderm and SK hepa- 
toma cells with this genomic aFGF probe (Fig. 4 A). Similar 
results  were  obtained  with  an  aFGF  oligomer  probe  (not 
shown).  Actin  mRNA  was  also  used  to  control  for  the 
amount of RNA  loaded  (Fig.  4  B). 
Differentiated F9 Cells Contain FGF-like Molecules 
Analysis of 3T3 cell and endothelial cell stimulatory activity 
derived from F9 stem cells and differentiated cells strongly 
indicated  that  FGFs  were  expressed  only  after differentia- 
tion. However, mRNAs that hybridized with probes for both 
acidic and basic FGF were detected in both stem and differ- 
entiated cells. To determine if these FGF messages were be- 
ing translated into immunoreactive but biologically inactive 
Figure 3. Expression of bFGF mRNAs. 
Poly A ÷ RNA (5 #g/lane) from F9 stem 
cells (A-C, lane 1 ); F9 cells treated with 
RA,  but2 cAMP,  and  theophylline  for 
4 d  (A-C,  lane  2);  and  SK  hepatoma 
cells  (A-C,  lane  3).  (A) bFGF cDNA 
probe; (B) actin cDNA probe, same blot 
as  A;  (C)  laminin  B1  and  J31  cDNA 
probes. Exposure times were 3 d (bFGF), 
1 h (actin), or 2 h (laminin B1 and J31). 
(A, large arrow) The position of the ac- 
tin mRNA seen in B when this same blot 
was rehybridized using the actin probe. 
(C, arrowheads) Positions of laminin BI 
mRNA at 6.2  kb (top arrowhead) and 
J31 mRNA at 2.2 kb (bottom arrowhead) 
in parietal endoderm (C,  lane 2). 
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mRNAs.  POly A  ÷  RNA  (5 
~g/lane) from F9 stem cells (.4 
and B, lane 1 ); F9 cells treated 
with RA, but2 cAMP, and the- 
ophylline for 4  d  (A and B, 
lane  2);  and  SK  hepatoma 
cells (A and B,  lane 3).  (A) 
aFGF  cDNA probe, 1.5  x 
106 cpm/ml; (B) actin cDNA 
probe. Exposure time was 1 d 
for aFGF and I h for actin. (A, 
arrowhead)  Position of  the 
aFGF mRNA in parietal en- 
doderm  cells (lane 2).  (A, 
arrow) Position of the  actin 
probe binding  to this blot when 
rehybridized using the  actin 
probe (B). 
proteins, both cell types were analyzed for FGF content by 
Western blot analysis and biosynthetic labeling studies. 
Several  attempts using heparin-Sepharose  chromatogra- 
phy followed by dialysis and concentration of the sample for 
Western analysis failed to yield reproducible results, primar- 
ily because of protein loss. To circumvent these problems, 
we used a modified heparin-Sepharose batch technique for 
the isolation of the FGFs (see Materials and Methods). Pro- 
teins from the F9 stem and differentiated F9 cell extracts that 
remained bound to heparin-Sepharose after washing with 
buffer containing 0.8 M NaCI were dissociated from the res- 
in by boiling  in  Laemmli's buffer (Laemmli,  1970),  and 
processed for routine one-dimensional gel electrophoresis. 
Subsequent electrophoretic transfer (Western)  blotting was 
performed and the nitrocellulose-bound proteins  were re- 
acted with polyclonal antibodies directed against acidic or 
basic FGF (Wadzinski et al.,  1987)  (Fig. 5). 
Affinity-purified rabbit antibodies raised against peptide 
fragments corresponding to (a) an internal region of bFGF 
(amino acid residues 33-43) (Fig. 5 a, lanes 1-4) and (b) the 
amino-terminal end  (amino  acid  residues  1-12) of bFGF 
(Fig. 5 A, lanes 6-9) reacted with a single protein band of 
18.4 kD from differentiated F9 parietal endoderm cells (Fig. 
5 A, lanes 4 and 9).  This band comigrated with bFGF de- 
rived from SK hepatoma cells, which was also recognized 
by these antibodies as a single, 18.4-kD protein species (Fig. 
5 A, lanes 2 and 6). No immunoreaction occurred with these 
antibodies  tested  in  parallel  against  brain-derived  aFGF 
(Fig. 5 A, lanes 3 and 8) or proteins from F9 stem cells (Fig. 
5 A, lanes 1 and 7). 
An affinity-purified  rabbit antibody, raised against the car- 
boxyl-terminal region of aFGF (amino acid residues 59-90), 
also reacted with differentiated F9 cell proteins, recognizing 
a band of ~15 kD (Fig. 5 B, lane 4). The molecular weight 
of this  F9  protein,  15,000, corresponds  to  that of brain- 
derived aFGF recognized by this antibody as a doublet (Fig. 
5 B, lane 2). There was no cross-reactivity of this antibody 
with SK hepatoma-derived bFGF (Fig. 5 B, lane 3) or with 
F9 stem cell extract tested in parallel (Fig. 5 B, lane/). The 
molecular weights of these proteins were calculated by com- 
parison to Coomassie blue-prestained markers (Fig.  5 A, 
lane 5). These studies clearly establish the presence of fac- 
tors with antigenic determinants and molecular weights char- 
acteristic of both basic and acidic FGF in cell extracts of 
differentiated F9 cells, not detected in F9 stem cells. 
FGFs Are Synthesized by Differentiated b-9 Cells But 
Not by F9 Stem Cells 
Our Western blot analysis indicated the presence of both 
aFGF and bFGF proteins in F9 differentiated  but not F9 stem 
cell extracts. To demonstrate synthesis of these factors, 6  x 
108 F9 stem and 1 ×  108 differentiated cells were metaboli- 
cally labeled and the FGFs were immunoprecipitated using 
the  antibodies  described  above.  After  radiolabeling  with 
[35S]methionine for 4  h,  the cells were harvested and the 
cell extract immunoprecipitated with (a) preimmune sera, 
(b)  the  affinity-purified polyclonal antibodies  against  the 
amino-terminal  end  of bFGF,  or  (c)  the  affinity-purified 
antibodies directed against the carboxyl-terminal region of 
aFGF  (Wadzinski et  al.,  1987).  The  immunoprecipitated 
proteins  were  separated  by  one-dimensional  Na2DodSO4 
gel electrophoresis and autoradiographed (Fig. 6). No spe- 
cific radiolabeled proteins were  immunoprecipitated from 
F9 stem (Fig. 6, lanes 1-4) or F9 differentiated (Fig. 6, lanes 
5-8) cell cytosol, after a 4-h labeling, by the bFGF antibod- 
ies (Fig. 6, lanes 2 and 6) as compared with its preimmune 
sera (Fig. 6, lanes I and 5). A single 20-21-kD radiolabeled 
protein was precipitated with the aFGF antibodies from the 
extract of differentiated cells (Fig. 6, lane 8), which was not 
seen in the stem cell extract (Fig. 6, lane 4) or in the preim- 
mune sera immunoprecipitate (Fig. 6, lanes 3 and 7). These 
studies indicate the presence of a newly synthesized protein, 
immunoreactive with an  antibody specific to aFGF,  only 
within F9 cells after differentiation. 
The Western blot analysis demonstrated both acidic and 
basic  FGF-like molecules to be present  in  F9  cells after 
differentiation. The absence of specific proteins immunopre- 
cipitated by the antibody directed against the amino terminus 
of bFGF is probably due to the inability of these antibodies 
to effectively  recognize rodent bFGF proteins in native form. 
One of us (T.  Kurokawa) has recently determined that the 
amino-terminal sequence of rodent bFGF differs from that 
of bovine bFGF (Kurokawa et al.,  1987).  Rat bFGF has an 
amino acid deletion at residue position 9, within the region 
of the bovine sequence to which this antibody is raised. If 
mouse bFGF has the same deletion, it may be difficult to im- 
munoprecipitate native mouse F9 cell-derived bFGF with 
this antibody. 
Discussion 
We have determined that F9 teratocarcinoma stem cells do 
not synthesize FGF, but do express this potent class of mito- 
gens after the induction of differentiation with RA and buh 
cAMP.  F9  stem cells do contain stimulatory activities for 
BALB/c 3T3 cells with characteristics different from FGE 
The activity from the stem cells that does not bind heparin 
is increased by acid treatment, is inhibitory for endothelial 
cells (in the presence and absence of FGF) in vitro and is a 
potent stimulator of angiogenesis in vivo, (observations in 
the  chick  chorioallantoic  membrane  assay;  unpublished 
data). The endothelial cell inhibitory activity can be partially 
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FGF  in heparin  affinity-purified 
F9 cell extracts. (A) Rabbit anti- 
body directed against an internal 
region of bFGF was used (lanes 
1-4) to analyze extracts from F9 
stem  cell  proteins  (A,  lane  1), 
heparin affinity-purified SK hepa- 
toma-derived bFGF (400 ng) (A, 
lane  2),  brain-derived  heparin 
affinity-purified  aFGF  (250  ng) 
(A, lane 3), and extracts from F9 
parietal  endoderm  cells (A, lane 
4).  A  rabbit  antibody  directed 
against  the  amino  terminus  of 
bFGF  was  used  (lanes  6-9)  to 
analyze  equivalent  amounts  of 
SK hepatoma cell-derived  bFGF 
(lane  6),  F9  stem  cell  extracts 
(lane 7), brain-derived heparin purified aFGF (lane 8), and F9 pa- 
rietal endoderm  cell extracts (lane 9).  (B) A rabbit antibody di- 
rected  against  aFGF was used  to analyze  equivalent  samples  as 
above:  extracts  from F9  stem cells  (B,  lane  1),  highly purified 
brain-derived  aFGF (B, lane 2),  SK hepatoma cell-derived bFGF 
(B, lane 3), and F9 parietal endoderm cell extracts (B, lane 4). The 
amount of stem or differentiated F9 proteins used was below the de- 
tection of a 280 or 260 wavelength absorbance reading or a micro- 
protein  assay (Bio-Rad Laboratories),  indicating  it is <1  /~g per 
lane. The curvature of the bands visualized is sometimes observed 
in a Western analysis due to residual salt in association  with the 
sample and  is not due to protein overload.  Coomassie blue-pre- 
stained molecular  mass markers (small arrows) include proteins 
of 55, 43, 36, and 29 kD (lane 5). Large arrows, positive reaction 
products. 
removed by immunoadsorption with antibodies specific for 
TGF-/3,  suggesting that F9 stem cells synthesize a  TGF-~- 
like activity before differentiation. 
Teratocarcinoma stem cells,  when placed in an aberrant 
position in the adult organism, form very large tumors that 
eventually kill their host (Martin,  1980).  Folkman has pro- 
posed that all solid tumors must evoke angiogenesis, to grow 
beyond 1-2 mm  3 in diameter (Folkman,  1963). The activity 
in the stem cells, which is in part TGF-/3, appears to greatly 
decrease or disappear upon differentiation of the F9 cells in 
response to RA. This may prove to be an important correlate 
of the in vivo tumorigenicity of the undifferentiated F9 stem 
cells.  Alternatively,  the  expression of TGF-~ by  the  stem 
cells may be unrelated to their transformed state but rather 
characteristic  of undifferentiated  embryonic stem cells.  In 
support of this latter hypothesis, recent studies have shown 
that a maternal mRNA in Xenopus eggs encoding for a TGF- 
/~-like protein is localized to the region that eventually gives 
rise  to  embryonic  endoderm  cells  (Weeks  and  Melton, 
1987). 
The two other minor peaks of activity derived from the ex- 
tract of F9 stem cells have not been conclusively identified. 
The peak that elutes with 0.5 M NaCI most likely represents 
the  intracellular  PDGF-Iike factor that is known to be se- 
creted by undifferentiated F9 stem cells (Gudas et al.,  1983; 
Rizzino and Bowen-Pope,  1985). Of primary importance is 
the observation that none of the three activities are detected 
in the cytosol 3 d after the induction of differentiation.  5 d 
after treatment with RA and but2 cAMP,  the differentiated 
F9 parietal endoderm cells synthesize an entirely new class 
of mitogens, the FGFs. In a preliminary study, we have ex- 
amined extracts from F9 cells 7 d after treatment with RA 
and but2 cAMP and found •l.5-2-fold  more FGF than on 
day 5.  This may represent FGF that has accumulated over 
time, or an increased level of expression of FGF in the day 
7  F9 parietal endoderm cells. 
Significantly, the activity,made by F9 parietal endoderm 
cells  is  not  detected  in  conditioned  media.  Since  lack  of 
secretion  also  characterizes  acidic  and  basic  FGF  this 
finding  provides additional  evidence that the differentiated 
F9 activity is FGE That the F9 cell FGF-like activity is not 
secreted also serves to distinguish it from the int-2 and hst 
1 proteins. These proteins are related to the FGFs but both 
have gene sequences that predict a leader signal peptide se- 
quence that would facilitate secretion (Yoshida et al.,  1987; 
Bovi et al.,  1987). 
The  genes  for  acidic  and  basic  FGF  have been  cloned 
(Abraham et al., 1986; Jaye et al., 1986) and a variety of cell 
types have been identified that synthesize bFGF (for review 
see Klagsbrun et al.,  1986; Schweigerer et al.,  1987b), but 
few cells have been identified that synthesize aFGF (Lobb et 
al.,  1986).  Using a bFGF cDNA probe, we detect a major 
mRNA of 2.2 kb in both stem and differentiated F9 cells and 
an additional mRNA in stem cells at 3.8 kb.  Similar bFGF 
message  sizes  have  been  reported  in  human  fibroblasts 
(Steinfeld et al.,  1988).  We do not know the significance of 
the multiple transcripts for bFGF mRNA in F9 stem cells. 
The genomic aFGF probe detected a  6.0-6.3-kb mRNA in 
parietal endoderm that was not detectable in F9  stem cells 
and a 5.8-6.0-kb transcript that was visible in both cell types 
(Fig.  4).  That the size of aFGF mRNA from human brain 
stem (Jaye et al.,  1986), differs from that in F9 cells may be 
due to tissue-specific differences in the processing, or spe- 
cies differences in mRNA size.  Very few studies of aFGF 
mRNA are currently in the literature. 
That there were few differences in the steady-state levels 
of the major species of bFGF mRNA between the stem and 
parietal endoderm cells was surprising in light of the fact that 
there was no evidence in stem cells of FGF-like material by 
biological assay, biosynthetic studies, or Western blot analy- 
sis.  There  are  at  least  two possible  explanations  for this 
difference. First, the stem cell mRNA may not be translated 
into immunoreactive or biologically active protein.  This is 
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labeled proteins from F9 stem and parietal endoderm cells electro- 
phoresed on a 15 % NaDOdSO4 polyacrylamide gel. Proteins from 
extracts of F9 undifferentiated stem (lanes 1-4) and F9 parietal en- 
doderrn cells (lanes 5-8) were immunoprecipitated with the preim- 
mune serum ofbFGF antibody (lanes 1 and 5, respectively); or with 
the immune specific antibody directed against bFGF (amino acids 
1-12) (lanes 2 and 6, respectively); or immunoprecipitation with the 
preimmune serum of the aFGF antibody (lanes 3 and 7); or with 
the immune sera to aFGF (amino acid residues 136-145) (lanes 4 
and 8,  respectively). Antibodies were used at  1:300. Molecular 
weights were calculated by comparison to prestained molecular 
weight markers (solid line) including phosphorylase b (94,000), 
BSA (67,000), ovalbumin (43,000), carbonic anhydrase (30,000), 
soybean trypsin inhibitor (21,500) and alpha-lactalbumin (14,400). 
(Arrowhead) Radiolabeled proteins immunoprecipitated by specific 
antibodies and not recognized by the preimmune serum. 
a reasonable postulate since differential translation of c-myc 
has been similarly reported in the F9 system (Dony et al., 
1985).  Second, FGF may be synthesized by both the stem 
and differentiated cells but may not be detectable in the stem 
cells  because  of immediate  consumption  or  degradation, 
whereas the cytoplasmic constituents, i.e., heparan sulfate, 
synthesized only by the differentiated cells may better stabi- 
lize FGF protein. This explanation is argued against by the in 
vivo radiolabeling data (Fig. 6), which does not demonstrate 
synthesis of radiolabeled FGF in stem cells, even during a 
relatively short labeling period. It is also possible that the 
6.0-6.3-kb aFGF mRNA seen exclusively in parietal endo- 
derm cells encode the majority of FGF in these cells. 
A finding of consequence in this report is that factors with 
properties of acidic and basic FGFs are synthesized by em- 
bryonic parietal endoderm cells. The F9 cell system serves 
as a model for the differentiation of  the mouse blastocyst, and 
thus our results may indicate that FGFs are present in parietal 
endoderm in early embryogenesis. Recent studies by Kim- 
melman and Kirschner (1987) have identified a mRNA en- 
coding a bFGF-like protein in Xenopus embryos that is pres- 
ent throughout development, an indication that FGF may be 
endogenous to the developing embryo. Notably, in this sys- 
tem, the message abruptly increases during the midblastula 
transition, just before gastrulation and the development of 
mesoderm. 
What role might this class of mitogens serve in the de- 
veloping embryo? In the adult, FGFs are thought to play a 
primary role in stimulating neovascularization during wound 
healing and ovulation and in association with a  number of 
disease states.  However, vascularization would not be occur- 
ring in the embryo at the time our studies indicate these FGFs 
would first appear. A more likely possibility is that other cell 
types  such  as  epithelial  cells,  fibroblasts,  myoblasts  and 
chondrocytes are the targets for FGF at this point in em- 
bryonic development, as FGFs are known to stimulate the 
proliferation and/or differentiation of these cells. 
Finally, the FGFs appear likely to function as other than 
mitogens. FGF has been shown to induce neurite outgrowth 
in  PC12  cells,  a  morphologic change associated with the 
differentiation of these  neural  cells  (Togari et  al.,  1985; 
Wagner and  DAmore,  1986).  Slack et al.  (1987) demon- 
strated that bFGF and aFGF induces the formation of meso- 
derm in early embryonic ectodermal explants of  amphibians. 
bFGF was shown to act as a morphogen, causing the induc- 
tion of mesoderm independent of a mitogenic response. Fur- 
ther, the dose of FGF was critical in determining the type of 
mesodermal cells that resulted: low doses (2-30 ng/ml) gave 
rise to mesothelial and blood cells,  whereas higher doses 
(>30 ng/ml) resulted in the formation of muscle tissue.  These 
studies strongly suggest that FGFs can function as inducers 
of mesodermal tissue. Our studies implicate the parietal en- 
doderm of the mouse embryo as one potential source of these 
potent inducers of various mesodermal elements. 
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